1. Home
  2. NMAX vs MIRM Comparison

NMAX vs MIRM Comparison

Compare NMAX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMAX
  • MIRM
  • Stock Information
  • Founded
  • NMAX 1998
  • MIRM 2018
  • Country
  • NMAX United States
  • MIRM United States
  • Employees
  • NMAX N/A
  • MIRM N/A
  • Industry
  • NMAX
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • NMAX
  • MIRM Health Care
  • Exchange
  • NMAX NYSE
  • MIRM Nasdaq
  • Market Cap
  • NMAX 2.5B
  • MIRM 2.2B
  • IPO Year
  • NMAX 2025
  • MIRM 2019
  • Fundamental
  • Price
  • NMAX $13.27
  • MIRM $50.34
  • Analyst Decision
  • NMAX
  • MIRM Strong Buy
  • Analyst Count
  • NMAX 0
  • MIRM 12
  • Target Price
  • NMAX N/A
  • MIRM $63.17
  • AVG Volume (30 Days)
  • NMAX 1.7M
  • MIRM 397.8K
  • Earning Date
  • NMAX 08-15-2025
  • MIRM 08-06-2025
  • Dividend Yield
  • NMAX N/A
  • MIRM N/A
  • EPS Growth
  • NMAX N/A
  • MIRM N/A
  • EPS
  • NMAX N/A
  • MIRM N/A
  • Revenue
  • NMAX $175,718,517.00
  • MIRM $379,251,000.00
  • Revenue This Year
  • NMAX N/A
  • MIRM $35.83
  • Revenue Next Year
  • NMAX N/A
  • MIRM $16.83
  • P/E Ratio
  • NMAX N/A
  • MIRM N/A
  • Revenue Growth
  • NMAX 20.18
  • MIRM 69.31
  • 52 Week Low
  • NMAX $11.82
  • MIRM $28.56
  • 52 Week High
  • NMAX $265.00
  • MIRM $54.23
  • Technical
  • Relative Strength Index (RSI)
  • NMAX N/A
  • MIRM 69.78
  • Support Level
  • NMAX N/A
  • MIRM $48.78
  • Resistance Level
  • NMAX N/A
  • MIRM $50.05
  • Average True Range (ATR)
  • NMAX 0.00
  • MIRM 1.64
  • MACD
  • NMAX 0.00
  • MIRM 0.39
  • Stochastic Oscillator
  • NMAX 0.00
  • MIRM 87.92

About NMAX NEWSMAX INC

Newsmax Inc is a multi-platform media company. The company provides original news and lifestyle updates from its linear cable television and over-the-top (OTT) news channels, websites, proprietary database, publishing products, and e-commerce products. The Company uses original news and editorial content to draw large numbers of readers to its media outlets to sell advertising, print, and online information products. The Company's business operations are conducted through two operating segments, Broadcasting and Digital. The company generates maximum revenue from the Broadcasting Segment.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: